Aerosolized antibiotics: Do they add to the treatment of pneumonia?

Current Opinion in Infectious Diseases

Volumn 26, Issue 6, 2013, Pages 538-544

  Kollef, Marin H ^a   Hamilton, Cindy W ^b,c   Montgomery, A Bruce ^d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c Hamilton House   (United States)

^d Cardeas Pharma   (United States)

Author keywords

aerosolized antibiotics; pharmacokinetics; ventilator associated pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; AZTREONAM LYSINE; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; COLISTIN; DORIPENEM; FOSFOMYCIN; MONOBACTAM DERIVATIVE; MUCIN; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; PROPOFOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ACINETOBACTER; ADJUVANT THERAPY; ADULT RESPIRATORY DISTRESS SYNDROME; AEROSOL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; BRONCHOSPASM; CELL MEMBRANE TRANSPORT; CYSTIC FIBROSIS; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG WITHDRAWAL; ENTEROBACTERIACEAE; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; JET NEBULIZER; MEDICAL NEBULIZER; MEDICAL TECHNOLOGY; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; OUTCOMES RESEARCH; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY THERAPEUTIC DEVICE; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; REVIEW; SUPERINFECTION; SURVIVAL; TREATMENT OUTCOME; VENTILATOR; VENTILATOR ASSOCIATED PNEUMONIA;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, BACTERIAL; HUMANS; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 84887320214     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000004     Document Type: Review

References (35)

1. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262-268.
2. Bekaert M, Timsit JF, Vansteelandt S, et al. Attributable mortality of ventilatorassociated pneumonia: A reappraisal using causal analysis. Am J Respir Crit Care Med 2011; 184:1133-1139.
3. Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator- associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol 2012; 33:250-256.
4. Tamma PD, Putcha N, Suh YD, et al. Does prolonged beta-lactam infusions improve clinical outcomes compared to intermittent infusions? A metaanalysis and systematic review of randomized, controlled trials. BMC Infect Dis 2011; 11:181.
5. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: A systematic review and meta-analysis. Clin Infect Dis 2013; 56:272-282.
6. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34:1-14.
7. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008; 52:24-36.
8. Ehrmann S, Roche-Campo F, Sferrazza Papa GF, et al. Aerosol therapy during mechanical ventilation: an international survey. Intensive Care Med 2013; 39:1048-1056.
9. Mietto C, Pinciroli R, Patel N, Berra L. Ventilator associated pneumonia: evolving definitions and preventive strategies. Respir Care 2013; 58:990-1007.
10. Centers for Disease Control and Prevention. Ventilator-associated event (VAE) for use in adult patients (-18 years)
11. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic fibrosis inhaled tobramycin study group. N Engl J Med 1999; 340:23-30.
12. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178:921-928.
13. VanDevanter DR, Rose LM, Sprugel KH. 28-day inhalation toxicology of polymyxin E1, themajor active component of colistin, in rats and dogs (poster P236). Presented at European Cystic Fibrosis Congress June 6-9, 2001, Vienna, Austria.
14. McCoy KS. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. N Engl J Med 2007; 357:2310-2311.
15. Coulthard K. Maximizing the efficacy and safety of colistimethate therapy. Pediatr Pulmon 2008; 43:193-195.
16. Mendelman PM, Smith AL, Levy J, et al. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. AmRev Respir Dis 1985; 132:761-765.
17. NiedermanMS, Chastre J, Corkery K, et al. Bay41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 2012; 38:263-271.
18. Montgomery AB, Rhomberg P, Abuan T, Jones R. Synergistic effects for a combination of amikacin and fosfomycin against selected resistant Gramnegative pathogens (abstract 43023 and poster). Am J Respir Crit Care Med 2013; 187:A3236.
19. Lu Q, Yang J, Liu Z, et al. Nebulized ceftazidime and amikacin in ventilatorassociated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011; 184:106-115.
20. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009; 135:1223-1232.
21. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010; 45:1121-1134.
22. Hilas O, Ezzo DC, Jodlowski TZ. Doripenem (doribax), a new carbapenem antibacterial agent. Pharm Ther 2008; 33:134-180.
23. Sorbello A. Doripenem safety review. 2013. Available at www.fda.gov/ohrms/ dockets/ac/08/slides/2008-4364s1-05-FDA-Sorbello.pdf..
24. MacLeod DL, Barker LM, Sutherland JL, et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 2009; 64:829-836.
25. Trapnell BC, McColley SA, Kissner DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med 2012; 185:171-178.
26. Montgomery AB, Vallance S, Abuan T, et al. A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow Inline nebulizer system in mechanically ventilated patients (abstract 42767 and poster 42767). Am J Respir Crit Care Med 2013; 187:A3236.
27. Eschenbacher WL, Boushey HA, Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am Rev Respir Dis 1984; 129:211-215.
28. Miller DD, Amin MM, Palmer LB, et al. Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med 2003; 168:1205-1209.
29. Clark R, Heslet L, Abtonsen K, Donehower B. Evaluation of the disposition and safety of tobramycin solution for inhlalation in ventilator associated pneumonia or tracheobronchitis patients (poster). Presented at American Thoracic Society International Conferenc 2003, Seattle, WA
30. Abu-Salah T, Dhand R. Inhaled antibiotic therapy for ventilator- associated tracheobronchitis and ventilator-associated pneumonia: an update. Adv Ther 2011; 28:728-747.
31. Wood GC. Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia. Expert Rev Anti Infect Ther 2011; 9:993-1000.
32. Arnold HM, Sawyer AM, Kollef MH. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care 2012; 57:1226-1233.
33. Lu Q, Luo R, Bodin L, et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 2012; 117:1335-1347.
34. Zhanel GG, Adam HJ, Low DE, et al. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 2011; 69:291-306.
35. Alvarez S, Jones M, Berk SL. In vitro activity of fosfomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985; 28:689-690.